Galectin Therapeutics INC 8-K Filing
Ticker: GALT · Form: 8-K · Filed: Dec 8, 2025 · CIK: 1133416
| Field | Detail |
|---|---|
| Company | Galectin Therapeutics INC (GALT) |
| Form Type | 8-K |
| Filed Date | Dec 8, 2025 |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Galectin Therapeutics INC (ticker: GALT) to the SEC on Dec 8, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ange on which registered Common Stock $0.001par value per share GALT The Nasdaq).
How long is this filing?
Galectin Therapeutics INC's 8-K filing is 2 pages with approximately 738 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 738 words · 3 min read · ~2 pages · Grade level 10.4 · Accepted 2025-12-08 08:00:42
Key Financial Figures
- $0.001 — ange on which registered Common Stock $0.001par value per share GALT The Nasdaq
Filing Documents
- ef20060738_8k.htm (8-K) — 54KB
- 0001140361-25-044711.txt ( ) — 181KB
- galt-20251203.xsd (EX-101.SCH) — 4KB
- galt-20251203_lab.xml (EX-101.LAB) — 21KB
- galt-20251203_pre.xml (EX-101.PRE) — 16KB
- ef20060738_8k_htm.xml (XML) — 4KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders. At the 2025 Annual Meeting of Stockholders held on December 3, 2025, the stockholders of the Company elected each of the Company's directors that had been nominated to serve until the next annual meeting or until their successors are elected and have been qualified. The stockholders also approved a non-binding advisory resolution to approved executive compensation and recommended, by non-binding vote, the frequency with which the Company will conduct stockholder advisory votes on executive compensation. Finally, the stockholders ratified the selection of Cherry Bekaert LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2025; The final results of the voting on each matter of business at the 2025 Annual Meeting are as follows: Election of Directors Name Votes For Votes Withheld Broker Non-Votes Gilbert F. Amelio, Ph.D. 25,335,421 874,903 19,513,532 Benjamin S. Carson, Sr., M.D. 25,916,838 293,486 19,513,532 Kary Eldred 25,886,740 323,584 19,513,532 Kevin D. Freeman 25,827,896 382,428 19,513,532 Joel Lewis 25,688,709 521,615 19,513,532 Gilbert S. Omenn, M.D., Ph.D. 25,810,287 400,037 19,513,532 Marc Rubin, M.D. 25,875,306 335,018 19,513,532 Elissa J. Schwartz, Ph.D. 25,920,970 289,354 19,513,532 Harold H. Shlevin, Ph.D. 25,745,010 465,314 19,513,532 Richard E. Uihlein, Chairman 25,907,034 303,290 19,513,532 Richard A. Zordani 25,906,350 303,974 19,513,532 Vote on a non-binding advisory resolution to approve the compensation paid to Galectin's named executive officers, as disclosed in the proxy statement Votes For Votes Against Votes Abstain Broker Non-Votes 25,260,489 639,415 310,420 19,513,532 - 2 - Recommendation, by non-binding vote, the frequency with which Galectin will conduct stockholder advisory votes on executive compensation 1 year 2 years 3 years Abstain 3,616,
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Galectin Therapeutics Inc. Date: December 8, 2025 By: /s/ Jack W. Callicutt Jack W. Callicutt Chief Financial Officer - 4 -